July 1, 2025 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, is pleased to announce the appointment of Dr. Weichang Zhou as Chief Technology Officer (CTO). Leveraging his extensive industry experience in the biopharmaceutical field, Dr. Zhou will accelerate the globalization process of MediLink’s innovative pipeline.
With over 30 years of distinguished industrial experience, Dr. Weichang Zhou is recognized for his leadership and major contributions to biologics development and manufacturing. Dr. Zhou has held a series of senior executive leadership positions at WuXi, including executive Director, Chief Technology Officer and President of Global Biologics Development and Operations. Prior to joining WuXi in 2012, Dr. Zhou held senior leadership roles in CMC teams at multiple renowned companies, such as Genzyme Corporation (now part of Sanofi S.A), PDL BioPharma Inc., and Merck & Co. Inc. Dr. Zhou obtained a Ph.D. degree in natural sciences from the University of Hannover in 1989 and conducted postdoctoral research at German Society for Chemical Equipment, Chemical Technology & Biotechnology, Swiss Federal Institute of Technology Zurich (ETH-Zurich), and the University of Minnesota. Dr. Zhou was awarded the American Institute for Medical and Biological Engineering (AIMBE) Fellowship in 2002, was honored the ACS James M. Van Lanen Distinguished Service Award in 2010, was awarded the American Chemical Society Fellowship in 2013, was honored as CTO of the Year 2023 (Asia-Pacific Biopharma Excellence Awards) in 2024, and was honored the 2025 ECI Cell Culture Engineering Award.
"It is with great honor and excitement to join MediLink," said Dr. Weichang Zhou. "Standing at the forefront of biotechnology with its vibrant innovation and high-growth potential, MediLink has truly exciting positioning in the ADC field. I look forward to working alongside the MediLink team to accelerate the company’s innovative development and the future commercialization of core products, to ultimately deliver more high-quality ADC products to patients worldwide at an accelerated pace."
"We proudly welcome Dr. Weichang Zhou to our leadership team," said Dr. Tony Tongtong Xue, Chairman and CEO of MediLink. "Powered by our proprietary TMALIN® platform, MediLink has advanced multiple ADC programs into clinical stages in both China and the US, and has reached multiple global collaborations. Our leading program YL201 has been progressed into Phase III clinical trials as planned. CMC manufacturing is pivotal for biologics, especially ADCs. With Dr. Zhou’s extensive industry experience and profound scientific insight, his addition will definitely accelerate MediLink’s globalization strategy."
About MediLink
MediLink Therapeutics, founded in 2020, is a clinical stage biotech company dedicated to developing conjugated drugs for cancer patients around the globe. MediLink has developed proprietary linker-payload technologies, among which the TMALIN® (Tumor Microenvironment Activable LINker-payload) platform enables the generation of homogeneous ADC with high drug-antibody ratio and improved therapeutic window for the treatment of solid tumors. Based on the TMALIN® platform, twelve ADCs have entered into the clinical development stage in China and the US. MediLink aims to provide improved treatment options to address unmet medical needs of patients around the globe. The company is headquartered in Suzhou, China and has established R&D sites in Shanghai, China and Boston, US.
